Clinical trial NCT04834128: A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19
Official title: A Phase II Safety and Tolerability, Inter-patient Pre-defined Dose Study of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) in Patients Diagnosed With COVID-19
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: COVID - 19
Keywords: ATMP
Lead sponsor: TC Biopharm
Sponsor class: INDUSTRY
First posted: 2021-04-06
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: open-label, safety and tolerability, escalating dose, single arm study
Primary purpose: TREATMENT

Brief summary: A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.

Detailed description: The aim of this Phase II study is to evaluate the safety and tolerability of ex-vivo expanded gamma delta T-cells (TCB008) manufactured from a single allogeneic unmatched or partially, randomly matched, unrelated donor, in patients with COVID-19.

The trial is designed to identify an optimal, safe dose of allogeneic γδ T cells in a population of patients with COVID-19. There will be 4 patient Cohorts. Cohorts 1 - 3 will receive a pre-defined dosing schedule, with Cohort 4 being treated with a dose selected upon completion of the first 3 Cohorts. In order to investigate immunogenicity assessment/sensitisation effects, patients in the expansion cohort who do not experience adverse reactions meeting dose limiting toxicity (DLT) criteria after the first administration will receive re-infusion with the same dose on Day 10 after the first infusion.

Eligibility criteria: Inclusion Criteria:

1. Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF);

   - willingness and capability to complete all the study procedures
2. Age 18-65 years (inclusive) at the time of signing ICF
3. Any gender
4. Patients with a positive diagnosis of COVID-19 either identified in the community as at risk of progression of disease or

   * already hospitalized with new changes on CXR or CT scan compatible with COVID19, or
   * patients requiring supplemental oxygen, but for whom dexamethasone is not yet indicated according to current standard of care recommendations.

The product would be indicated for patients categorized as per the WHO ordinal scale 2,3 or 4: i.e., ambulatory (or community identified) patients with limitations of activity, judged as at risk for progression of disease, as well as hospitalized patients not yet requiring oxygen therapy or receiving non-invasive low flow oxygen therapy, which does not yet indicate the need to commence dexamethasone therapy.

Exclusion Criteria

1. Patients requiring high-flow oxygen therapy and/or dexamethasone according to the current standard of care.
2. Patients suffering from severe cognitive impairment or mental illness
3. Pregnant and/or lactating women
4. Patients participating in other CTIMP clinical studies at the same time
5. Active autoimmune disease or Graft versus Host Disease (GVHD)
6. Patients with any major comorbidity (e.g., diabetes, cardiovascular and pulmonary diseases, malignancies on active treatment) unless their pre-morbid Karnofsky performance status was ≥ 80%
7. Patients with documented history of immunological disorders
8. Immunocompromised patients defined as those with human immunodeficiency virus infection with a CD4 cell count of less than 200 per microliter or uncontrolled viremia, prolonged use of glucocorticoids or other immunomodulating medications, a history of bone marrow or organ transplantation
9. ALT / AST\> 5 times the upper limit of the normal
10. Neutrophils \<500 / mm3
11. Platelets \<50.000 / mm3
12. Patients known or suspected to have sensitivity against mouse immunoglobulins or iron-dextran.

Primary outcomes:
measure: Assessment of treatment emergent adverse events (AEs) - Safety
timeFrame: 30 and 90 days after IMP administration
measure: Incidence of dose-limiting toxicities (DLTs) - Tolerability
timeFrame: 30 and 90 days after IMP administration
measure: Establish Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) - Tolerability
timeFrame: Approx 1 year
Secondary outcomes:
Other outcomes:
measure: Persistence of gamma delta T cells
timeFrame: Approx 1 year
measure: Phenotype of gamma delta T cells
timeFrame: Approx 1 year
Locations:
city: Newcastle
country: United Kingdom
facility: Royal Victoria Infirmary
Study officials:
References: